This inventor holds 1 USPTO granted patent. Top assignee: University of California. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: Longen Zhou: Innovator in Pharmaceutical Compositions
Introduction
Longen Zhou is a prominent inventor based in Irvine, California. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of chronic myelogenous leukemia (CML). His innovative work focuses on developing compositions that address imatinib-resistant CML, showcasing his commitment to advancing medical science.
Latest Patents
Longen Zhou holds a patent for "Pharmaceutical compositions containing an indoyl isoquinoline containing compound and uses thereof." This patent outlines methods for treating chronic myelogenous leukemia, specifically targeting cases resistant to imatinib. The compositions involve administering a Rad51-inhibitor alongside a kinase inhibitor, with the Rad51 inhibitor featuring an indolyl isoquinoline structure and the kinase inhibitor being a BCR-ABL inhibitor. This innovative approach represents a significant advancement in cancer treatment.
Career Highlights
Longen Zhou is affiliated with the University of California, where he continues to engage in groundbreaking research. His work has not only contributed to the scientific community but has also paved the way for new therapeutic strategies in oncology. His dedication to research and innovation is evident in his patent and ongoing projects.
Collaborations
Longen Zhou collaborates with esteemed colleagues such as Wen-Hwa Lee and Phang-Lang Chen. These partnerships enhance the research environment and foster the development of novel solutions in the pharmaceutical field.
Conclusion
Longen Zhou's contributions to pharmaceutical innovations, particularly in the treatment of chronic myelogenous leukemia, highlight his role as a key inventor in the medical field. His work exemplifies the impact of research and collaboration in advancing healthcare solutions.